Skip to main content
Medinice S.A. logo

Medinice S.A. — Investor Relations & Filings

Ticker · ICE ISIN · PLMDNCE00016 LEI · 259400LGO9UDV1Y18Z11 WAR Manufacturing
Open in API
Filings indexed 761 across all filing types
Latest filing 2022-04-19 Share Issue/Capital Cha…
Country PL Poland
Listing WAR ICE

About Medinice S.A.

https://www.medinice.pl/?lang=2

Medinice S.A. is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions in the fields of cardiology and cardiac surgery. The company's mission is to create patient-focused technologies that improve the quality of life for individuals with cardiac diseases. Its portfolio consists of advanced medical devices, including Class III devices, which undergo a full research, development, and clinical trial process before market introduction. Key projects include CoolCryo, a cryoablation system; AtriClamp, for left atrial appendage closure; and PacePress, a specialized compression band used after cardiac device implantation procedures.

Recent filings

Filing Released Lang Actions
Zawiadomienie NN 15.04.2022
Share Issue/Capital Change Classification · 99% confidence The document is a formal notification dated April 15, 2022, from Medinice S.A., referencing Polish public offering laws (art. 87 ust. 1 pkt 2b). It explicitly states that certain funds managed by Nationale-Nederlanden have reduced their total holding of company shares below the 5% threshold of votes at the General Meeting of Shareholders following a capital increase registration. The core content is a notification about a change in significant share ownership (crossing a threshold). This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and serves as a direct regulatory disclosure, not a comprehensive report.
2022-04-19 Polish
Zawiadomienie w trybie art. 69 ustawy o ofercie publicznej - Content (PL)
Major Shareholding Notification Classification · 98% confidence The document text, written in Polish, describes a notification received by the Issuer (Emitent) from Nationale-Nederlanden regarding a decrease in their shareholding below the 5% threshold, as mandated by Article 69 of the Public Offering Act. This type of filing concerns changes in significant share ownership levels. The document explicitly states that the scan of the notification is attached to the current report. Given the subject matter (change in significant shareholding) and the short length (874 chars) indicating it is an announcement referencing an attached document, the most appropriate classification is Major Shareholding Notification (MRQ).
2022-04-19 Polish
Przekazanie przez spółkę JitMed sp. z o.o. informacji o wcześniejszym zamknięciu badania klinicznego - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a short announcement (842 characters) from the Management Board ('Zarząd') of Medinice S.A. regarding its subsidiary closing a clinical trial for a medical device ('AtriClamp') and notifying the relevant regulatory office ('Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych'). This concerns a specific regulatory/product development event, but it is not a full financial report (10-K, IR), an earnings release (ER), or a formal legal proceeding report (LTR). Since it is a specific regulatory notification about a product/trial status, and it is not a general regulatory filing fallback (RNS), it best fits the category for updates on specific regulatory or legal matters. Given the options, 'Legal Proceedings Report' (LTR) is the closest fit for reporting on the status of a clinical trial and regulatory notification, although it is not strictly a lawsuit. However, considering the context of medical device regulation and trial closure, it is a specific regulatory update. If a more specific 'Regulatory Product Update' existed, it would fit there. Given the provided definitions, and since it is a formal notification to a regulatory body about a product status change, it is most appropriately classified as a specific regulatory/legal update. Since LTR is for 'significant lawsuits, regulatory actions, or legal matters', and this is a regulatory action/notification, I will select LTR, though RNS is a possibility if LTR is too narrow. Given the specificity of the content (clinical trial closure notification to a regulator), LTR seems more appropriate than the general RNS fallback.
2022-04-15 Polish
Zawiadomienie Wojciech Wróblewski
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakejaeh*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). This regulation (MAR - Market Abuse Regulation) mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs). The content details a transaction (conversion of warrants into shares) by a member of the Supervisory Board ('CZŁONEK RADY NADZORCZEJ') of the issuer (MEDINICE SPÓŁKA AKCYJNA). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). Matching this to the provided definitions: - Code DIRS: Director's Dealing (Report of personal share transactions by company directors and executives (insider trades)). This is the most accurate fit.
2022-04-13 Polish
Zawiadomienie Bogdan Szymanowski
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakejaeh, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction involving a member of the Supervisory Board (Bogdan Szymanowski) of the issuer (MEDINICE SPOŁKA AKCYJNA). Specifically, it reports the conversion of Series A warrants into Series F shares. This type of filing, reporting personal share transactions by company directors or executives (insider trades) under MAR regulations, directly corresponds to the definition of Director's Dealing.
2022-04-13 Polish
Zawiadomienie Agnieszka Rosińska
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakejaeh*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). It details a transaction involving a member of the Supervisory Board (AGNIESZKA ROSIŃSKA) of MEDINICE SPÓŁKA AKCYJNA, specifically the conversion of warrants into shares. This type of filing, reporting personal share transactions by company directors and executives (insider trades) under MAR (Market Abuse Regulation), directly corresponds to the 'Director's Dealing' category. Filing Category Mapping: - Director's Dealing (Code: DIRS): Report of personal share transactions by company directors and executives (insider trades). This is a perfect match.
2022-04-13 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.